Incannex Healthcare Net Income From Continuing Ops Over Time
| IXHL Stock | USD 0.27 0.01 3.57% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Incannex Healthcare Performance and Incannex Healthcare Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Incannex Healthcare. Market participants price Incannex higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Incannex Healthcare assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Incannex Healthcare is measured differently than its book value, which is the value of Incannex that is recorded on the company's balance sheet. Investors also form their own opinion of Incannex Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Incannex Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incannex Healthcare's market value can be influenced by many factors that don't directly affect Incannex Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incannex Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Incannex Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Incannex Healthcare's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income From Continuing Ops Analysis
Compare Incannex Healthcare and related stocks such as Zhengye Biotechnology, Sharps Technology, and Agenus Inc Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZYBT | 46.5 M | 46.5 M | 46.5 M | 46.5 M | 46.5 M | 46.5 M | 46.5 M | 46.5 M | 46.5 M | 46.5 M | 46.5 M | 46.5 M | 55.7 M | 37.5 M | 13.5 M | 12.1 M | 11.5 M |
| STSS | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (4.7 M) | (4.6 M) | (7.6 M) | (9.3 M) | (8.4 M) | (8.8 M) |
| AGEN | (23.3 M) | (23.3 M) | (11.3 M) | (30.1 M) | (42.7 M) | (88.1 M) | (127.1 M) | (120.7 M) | (162 M) | (111.6 M) | (182.9 M) | (28.7 M) | (228.7 M) | (283 M) | (232.3 M) | (209 M) | (198.6 M) |
| LUCD | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (8.3 M) | (28.1 M) | (56.2 M) | (56.8 M) | (45.5 M) | (41 M) | (43 M) |
| SCLX | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (47.5 M) | (1 M) | (23.4 M) | (110.8 M) | (72.8 M) | (83.7 M) | (87.9 M) |
| CGTX | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (7.8 M) | (11.7 M) | (43.6 M) | (22.8 M) | (34 M) | (30.6 M) | (32.1 M) |
| SEER | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (16 M) | (32.8 M) | (71.2 M) | (93 M) | (91 M) | (86.6 M) | (77.9 M) | (81.8 M) |
| SXTC | 141.5 K | 141.5 K | 141.5 K | 141.5 K | 141.5 K | 141.5 K | 1.2 M | 1.2 M | 1.5 M | (10.3 M) | (2.7 M) | (5.7 M) | (5.9 M) | (3.1 M) | (3.3 M) | (3 M) | (3.1 M) |
| IRD | (24.6 M) | (24.6 M) | (24.6 M) | (24.6 M) | (24.6 M) | (24.6 M) | (24.6 M) | (24.6 M) | (24.6 M) | (24.6 M) | (24.6 M) | (56.7 M) | 17.9 M | (10 M) | (57.5 M) | (51.8 M) | (49.2 M) |
| TTRX | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (1.8 M) | (2 M) | (2.1 M) |
Incannex Healthcare and related stocks such as Zhengye Biotechnology, Sharps Technology, and Agenus Inc Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Incannex Healthcare Ltd | IXHL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 8 Century Circuit, |
| Exchange | NASDAQ Exchange |
USD 0.27
Check out Incannex Healthcare Performance and Incannex Healthcare Correlation. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Incannex Healthcare technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.